Paul Vauterin Moves from CTO to COO at BioLizard
Embracing the next phase of AI-driven innovation in life sciences Paul Vauterin has transitioned from Chief Technology Officer (CTO) to Chief Operating Officer (COO) at BioLizard, reflecting a shift in focus towards helping organisations integrate AI into their...
Beyond animal testing in drug development
A biological gap largely drives this massive failure rate. Natural differences between humans and testing species like mice or monkeys mean that applying animal results to humans is often inaccurate. History provides several high-profile examples of this disconnect....
How spatial biology improves clinical trial success in oncology
In oncology, the drug development path is unique: Phase 0 and Phase I trials are typically conducted in patients rather than healthy volunteers, allowing for early assessment of efficacy and patient selection alongside safety. Yet, even with this early clinical...